TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs from lab to clinic and have enabled the company to discover potential new drug formulations and delivery methods as well as create clinical protocols for psychedelic compounds and support clinical-stage development of CYBN’s proprietary CYB003…